Close Menu

NEW YORK (GenomeWeb) — Lucigen has entered phase two of a five-year, $1.7 million, Small Business Innovation Research grant from the National Institute of Allergy and Infectious Diseases to develop a nucleic acid test for three types of viral hemorrhagic fever: Ebola, Lassa, and Marburg.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: Readfish tool for targeted nanopore sequencing, genomic diversity of barley and wheat, and more.

The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.

A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.

The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.